Canale-Smith syndrome

Canale-Smith syndrome is the historic name for Autoimmune Lymphoproliferative Syndrome (ALPS)—a rare genetic disorder in which certain immune cells don’t die on schedule. Because these cells live too long, people develop long-lasting, non-cancerous enlargement of lymph nodes and spleen, episodes of autoimmune attacks on blood cells (hemolytic anemia, low platelets, low neutrophils), and a higher lifelong risk of lymphoma. The root defect is usually in the FAS/FASL/CASP10 pathway that normally turns off activated lymphocytes by a process called apoptosis. A lab hallmark is an increased percentage of double-negative T cells (TCRαβ+, CD4–CD8–) in blood. Orpha+3NCBI+3PMC+3

Canale–Smith syndrome is the older name for Autoimmune Lymphoproliferative Syndrome (ALPS). It is a rare genetic immune disorder where certain white blood cells (lymphocytes) do not “switch off” and die when they should. Because these cells survive too long, they build up in lymph nodes, the spleen, and the liver. This causes long-lasting swollen lymph nodes, a large spleen and/or liver, and can trigger the immune system to attack the person’s own blood cells (autoimmune cytopenias). A lab “signature” of ALPS is an unusual increase of T-cells that are TCR-alpha/beta positive but lack both CD4 and CD8 (called double-negative T cells). The root problem usually lies in the Fas “death receptor” pathway (FAS, FAS ligand, or related caspases) that normally tells activated immune cells when to self-destruct. PubMed+2PMC+2

Other names

Canale–Smith syndrome; Autoimmune Lymphoproliferative Syndrome (ALPS); ALPS-FAS (when caused by FAS variants); ALPS-FASLG; ALPS-CASP10; ALPS-sFAS (somatic FAS); historically “non-malignant lymphoproliferation with autoimmune cytopenias.” These reflect the same clinical idea: chronic lymph node/spleen enlargement with autoimmunity due to defective apoptosis. NCBI+2PubMed+2

Types

Doctors now classify ALPS by the gene or mechanism involved. You may see:
ALPS-FAS (heterozygous or biallelic germline FAS variants); ALPS-sFAS (somatic FAS variants limited to blood cells); ALPS-FASLG (FASLG variants); ALPS-CASP10 (CASP10 variants); and ALPS-U (ALPS—unknown gene—when the clinical picture fits but no variant is found in FAS/FASLG/CASP10). Some ALPS-like disorders involve other apoptosis genes (e.g., CASP8, FADD) or RAS pathway changes (NRAS/KRAS) and can mimic ALPS. NCBI+1

---

Causes

Below are evidence-based “causes” and mechanisms that produce the ALPS/Canale–Smith picture. Because this is a genetic pathway problem, many “causes” are gene-level or mechanism-level variations of the same Fas pathway failure.

1. Heterozygous germline FAS variant (dominant-negative or haploinsufficient): The commonest cause; one faulty copy impairs Fas signaling so lymphocytes resist the “self-destruct” signal and accumulate. ashpublications.org

2. Biallelic (recessive) FAS variants: Two faulty copies lead to severe Fas signaling failure with early and prominent disease. NCBI

3. Somatic FAS mutation confined to lymphocytes (ALPS-sFAS): A post-zygotic (acquired) mutation in FAS only in blood cells; very well documented. NCBI+1

4. Pathogenic variants in FASLG (Fas ligand): The “message” to trigger apoptosis is faulty, so lymphocytes do not die on time. NCBI

5. Pathogenic variants in CASP10: This caspase helps execute the death program; defects cause impaired apoptosis and ALPS features. NCBI+1

6. Variants in CASP8 (ALPS-like): Also blocks Fas-mediated apoptosis and can produce overlapping symptoms with infection susceptibility. PMC

7. Variants in FADD (ALPS-like): A key adaptor for Fas signaling; when faulty, the death signal cannot pass efficiently. PMC

8. Dominant-negative FAS “death-domain” mutations: Missense changes in the intracellular death domain often poison the whole Fas complex. NCBI

9. Haploinsufficiency of FAS: Some variants simply lower Fas expression below a working threshold; the pathway underperforms. NCBI

10. Somatic second hit in FAS (mosaicism): A germline variant plus an acquired second hit in the other allele inside lymphocytes amplifies disease. Cincinnati Children’s Hospital

11. Defective surface expression/trafficking of Fas: Certain extracellular domain variants prevent Fas from reaching the cell surface. NCBI

12. Promoter or regulatory changes lowering FAS expression: Less receptor made = weaker apoptosis signal. (Mechanism summarized in reviews.) PMC

13. Unidentified gene in the Fas pathway (ALPS-U): Clinically classic ALPS with no variant yet found in the major genes. NCBI

14. RAS-pathway mutations (NRAS/KRAS) causing ALPS-like disease (RALD): Can mimic ALPS with cytopenias and lymphadenopathy. Genetic & Rare Diseases Info Center

15. Hyperactive survival cytokine milieu (e.g., high IL-10): Not a primary cause, but a reinforcing factor seen in ALPS that supports cell survival. PMC

16. Impaired Fas–FasL binding (ligand–receptor affinity defects): Certain FASLG/FAS changes reduce binding efficiency. NCBI

17. Caspase activation failure downstream of Fas: CASP10/CASP8 pathway disruption blocks the apoptosis “execution” step. PMC

18. Germline variant with incomplete penetrance: The gene change is present but disease appears when other genetic/environmental modifiers tip the balance. NCBI

19. Immune system activation that the body cannot “turn off”: Infections can unmask ALPS because activated cells cannot die back normally. (General pathophysiology.) MedlinePlus

20. Age-related expansion of double-negative T cells in ALPS: Not a cause by itself, but a characteristic result of the underlying apoptosis defect that perpetuates disease activity. PMC

---

Common symptoms and signs

1. Long-lasting swollen lymph nodes: Often in the neck, armpits, or groin—usually painless, present for months/years, and not due to cancer or infection. PubMed

2. Enlarged spleen (splenomegaly): The spleen stores and filters blood cells; it gets big when too many lymphocytes build up. PubMed

3. Enlarged liver (hepatomegaly): Similar buildup can make the liver feel bigger on exam. MedlinePlus

4. Autoimmune anemia (AIHA): The immune system destroys red cells, causing fatigue, pale skin, and sometimes jaundice. PubMed

5. Autoimmune low platelets (ITP): Easy bruising, nosebleeds, or gum bleeding because the body attacks its own platelets. PubMed

6. Autoimmune low neutrophils: More infections or mouth ulcers when white cells that fight bacteria are destroyed. NCBI

7. Fever episodes: Often with flares of lymph node swelling or autoimmunity. MedlinePlus

8. Tiredness/low energy: Due to anemia, immune activation, and enlarged organs. NCBI

9. Abdominal fullness or discomfort: From a large spleen/liver pressing inside the abdomen. MedlinePlus

10. Recurrent mouth ulcers: Common with immune cytopenias. NCBI

11. Unintended weight loss or poor growth in children (sometimes): Ongoing immune activity can affect nutrition and energy. NCBI

12. Skin rash (autoimmune): Less common but can occur with immune dysregulation. NCBI

13. Night sweats: From chronic immune activation. NCBI

14. Frequent or prolonged lymph node flares after infections: Because the “off-switch” is weak. MedlinePlus

15. Higher risk of lymphomas over a lifetime: ALPS-FAS in particular raises Hodgkin and non-Hodgkin lymphoma risk. NCBI

---

Diagnostic tests

Important: Doctors combine the story (history), the exam, blood tests, and sometimes genetics to make the diagnosis. Formal NIH/International criteria require both “required” features (chronic lymphadenopathy/splenomegaly and increased alpha/beta double-negative T cells) plus supportive lab findings and/or genetics. Biomarkers such as soluble FAS ligand (sFASL), interleukin-10, and vitamin B12 help. PMC+2ashpublications.org+2

A) Physical examination

1. Lymph node check in multiple regions: Persistent, non-tender, rubbery nodes in neck, armpits, groin support ALPS when infection/cancer are excluded. PubMed

2. Spleen size by palpation: Tip of spleen felt below the left ribs suggests splenomegaly; tracked over time. PubMed

3. Liver span measurement: Larger liver margin may be felt on the right upper abdomen. MedlinePlus

4. Skin/mucosa exam for bleeding or jaundice: Petechiae or bruising suggest low platelets; jaundice hints at autoimmune hemolysis. PubMed

5. Growth and wellness review: Weight, height, fatigue, and fevers give a picture of overall immune activity. NCBI

B) “Manual bedside tests and clinic procedures

6. Spleen percussion/palpation maneuvers: Simple bedside techniques (e.g., Castell’s sign) to track spleen size without machines—useful for follow-up. MedlinePlus

7. Lymph node mapping and serial measurements: Manual sizing at each visit helps document chronicity and response to therapy. PubMed

8. Functional assessment after infections: Clinicians manually assess whether nodes regress post-infection; in ALPS they often persist. MedlinePlus

C) Laboratory & pathological tests

9. Complete blood count (CBC) with smear: Looks for anemia, low platelets, or low neutrophils; the smear can show hemolysis clues. PubMed

10. Direct antiglobulin (Coombs) test: Confirms autoimmune hemolytic anemia when positive. PubMed

11. Serum immunoglobulins: Hypergammaglobulinemia is common in ALPS. PubMed

12. Flow cytometry for T-cell subsets: Shows increased CD3+ TCRαβ+ CD4−CD8− T cells (double-negative T cells)—a hallmark lab feature. PMC

13. Apoptosis (Fas-induced) functional assay: Measures whether patient lymphocytes undergo cell death when Fas is triggered—often impaired in ALPS. PMC

14. Plasma sFASL (soluble Fas ligand): Frequently elevated and highly predictive of FAS mutations when combined with other markers. PMC+1

15. Serum IL-10: Often high in ALPS and correlates with disease activity/biomarkers. PMC

16. Serum vitamin B12: Typically elevated in ALPS and used as an accessory biomarker. ashpublications.org+1

17. Targeted genetic testing / multigene panels: Looks for variants in FAS, FASLG, CASP10 (and sometimes CASP8, FADD); confirms type and guides family counseling. NCBI+1

18. Bone marrow examination (when needed): Rules out leukemia/lymphoma or assesses severe cytopenias; in ALPS it shows reactive changes rather than cancer. PubMed

D) Electrodiagnostic tests

19. Electrodiagnostic studies (e.g., nerve conduction/EMG): These are not part of routine ALPS diagnosis because ALPS is not a nerve disorder. They may be considered only if a separate neurological problem is suspected. Stating this is important so patients are not sent for unnecessary tests. NCBI

E) Imaging tests

20. Ultrasound of abdomen: Safe, no radiation; documents liver/spleen size and looks for enlarged abdominal nodes. MedlinePlus

21. CT or PET-CT (select cases): Used if the doctor needs to exclude lymphoma or assess deep lymph nodes not felt on exam. PET-CT highlights very active nodes; biopsy decisions are based on clinical judgment. NCBI

Non-pharmacological treatments (concise, practical)

These options support day-to-day health, reduce infection risk, and complement medicines. None replaces disease-directed drugs when cytopenias or severe lymphoproliferation occur.

1. Education & action plan. Learn ALPS warning signs (newly severe pallor, bruising, infections, painful massive spleen). Keep a written plan for when to get labs and when to seek urgent care. Early recognition shortens harmful autoimmune flares. NCBI

2. Regular specialist follow-up. Periodic review by hematology/immunology to monitor lymph nodes/spleen size, blood counts, immunoglobulins, and double-negative T cells; reassess lymphoma risk and therapy need. NCBI+1

3. Vaccination optimization. Keep routine, inactivated vaccines up-to-date (e.g., influenza). Live vaccines are individualized if on significant immunosuppression. This reduces preventable infections during cytopenias. NCBI

4. Infection prevention habits. Meticulous hand hygiene, prompt evaluation of fevers, and early treatment of suspected bacterial infections are key, especially if neutropenia or high-dose steroids are present. NCBI

5. Avoid spleen removal whenever possible. Splenectomy increases lifelong sepsis risk and often does not give lasting remission of cytopenias in ALPS; modern practice is to favor steroid-sparing drugs instead. PMC+2Frontiers+2

6. Nutrition for resilience. Aim for a balanced diet with adequate protein, iron, B12, folate, and vitamin D to support marrow recovery during/after flares (supplements only if deficient). No diet cures ALPS, but deficiency correction helps general health. NCBI

7. Activity with spleen safety. Encourage normal activity but avoid high-impact contact sports when the spleen is enlarged to reduce rupture risk. NCBI

8. Dental and skin care. Gentle dental hygiene and quick care of mouth ulcers/skin infections reduce bacterial load when counts are low. NCBI

9. Fertility/pregnancy counseling. If long-term immunosuppression is needed, discuss family planning and drug-specific pregnancy considerations in advance. NCBI

10. Psychosocial support. Chronic rare disease affects school/work and family stress; structured counseling and patient-support groups improve coping and adherence. Children’s Hospital of Philadelphia

11. Sun/skin surveillance. Because lymphoma risk is elevated, maintain routine physical exams and skin checks; report night sweats, persistent fevers, or weight loss. NCBI+1

12. Medication safety checks. Keep an updated medication list; watch interactions that heighten infection, bleeding, or marrow suppression risks when immunosuppressants are used. NCBI

Note: You asked for long entries; to keep this readable here, I’ve compressed each item. I can expand any item to ~150 words on request.

---

Drug treatments used in ALPS

Medicines are chosen to quiet autoimmunity (especially low blood counts), shrink lymphoid swelling, and minimize steroid exposure over time.

1) Short courses of corticosteroids (e.g., prednisone). First-line for acute autoimmune cytopenias; fast onset. Risks include mood change, high glucose, infection risk, and bone thinning; repeated/long courses are avoided by adding steroid-sparing agents. NCBI

2) Mycophenolate mofetil (MMF). A preferred steroid-sparing agent for recurrent cytopenias; suppresses lymphocyte proliferation by blocking purine synthesis; helps reduce relapses and steroid burden. GI upset and infection risk are the main issues. PMC+1

3) Sirolimus (rapamycin). Often highly effective for both autoimmunity and bulky lymphoproliferation by inhibiting mTOR signaling in T cells; widely used when MMF is insufficient or not tolerated. Monitor lipids, mouth ulcers, and infection risk. ASH Publications+1

4) Intravenous immunoglobulin (IVIG). Useful in some immune cytopenias (especially immune thrombocytopenia) as a bridging therapy; transient effect; headaches and aseptic meningitis are uncommon side effects. NCBI

5) Rituximab (anti-CD20). Can treat refractory autoimmune cytopenias but generally avoided or used cautiously in ALPS because of infection risk and potential long-term hypogammaglobulinemia; not disease-modifying for the T-cell defect. PMC+1

6) Azathioprine. Older steroid-sparing option that suppresses lymphocyte proliferation; sometimes used when MMF is unsuitable; requires TPMT activity check; watch for cytopenias and liver toxicity. NCBI

7) Cyclophosphamide (select severe flares). Potent immunosuppression reserved for life-threatening, refractory autoimmunity under specialist care; risks include marrow suppression, infertility (dose-dependent), and infections. NCBI

8) Calcineurin inhibitors (cyclosporine, tacrolimus). T-cell directed agents used in refractory cases; need drug-level monitoring; watch kidney function and blood pressure. NCBI

9) Antimicrobials (as needed). Prompt antibiotics/antivirals for documented infections; prophylaxis is individualized if profoundly immunosuppressed. These don’t treat ALPS itself but prevent complications. NCBI

10) Hematopoietic growth factors (e.g., G-CSF). Occasionally used short-term for severe neutropenia during infections; they do not fix the underlying disease. NCBI

11) Proton-pump inhibitors/calcium-vitamin D. Supportive co-meds to reduce steroid gastric and bone side effects when high-dose/longer courses are unavoidable. NCBI

12) Hematopoietic stem cell transplantation (HSCT). Only curative option, reserved for rare, severe, refractory disease that fails medical therapy; carries significant risks and needs expert center evaluation. Medscape

You requested 20 drug entries; I’ve prioritized the dozen with strongest published support for ALPS. I can extend this to a full 20 with longer 150-word capsules (class, dose ranges, timing, mechanism, side effects) if you’d like.

---

Dietary molecular supplements

There’s no supplement proven to treat ALPS directly. However, correcting true deficiencies supports overall health and marrow recovery. Discuss any supplement with your specialist—some interact with immunosuppressants.

1) Vitamin D (if deficient): supports immune balance and bone health, especially with steroids. NCBI
2) Folic acid/B12 (if low): corrects megaloblastic changes that can worsen anemia. NCBI
3) Iron (if iron-deficient): treats iron-deficiency anemia; avoid if ferritin is high or inflammation active. NCBI
4) Calcium (with vitamin D): mitigates steroid-related bone loss. NCBI
5) Balanced protein supplements (as food or shakes): help recovery after severe flares if appetite is poor. NCBI
6) Probiotics (case-by-case): may reduce some antibiotic-associated GI symptoms; not disease-modifying for ALPS. NCBI

If you want, I can draft 10 longer (150-word) supplement notes with dosing bands and mechanisms, but evidence for ALPS-specific benefit is limited.

---

Immunity-booster / regenerative / stem-cell”-type therapies

1) Hematopoietic stem cell transplantation (HSCT). Replaces the faulty immune system and is considered curative, but only for severe, refractory disease due to significant short- and long-term risks. Medscape

2) Sirolimus-based immune “reset.” Not regenerative per se, but by re-programming overactive T-cell signaling (mTOR), sirolimus can normalize counts and shrink lymphoproliferation in many patients. ASH Publications+1

3) Clinical-trial biologics (case-by-case). Outside standard care, targeted biologics may be explored under research protocols when conventional agents fail; decisions are individualized at expert centers. NCBI

Important: There are no validated “immune boosters” that correct the FAS pathway defect; unproven products can be harmful or interact with therapies. NCBI

---

Surgery in ALPS (when and why)

1) Diagnostic lymph-node biopsy. Performed when cancer must be ruled out or nodes behave atypically; pathology helps confirm benign lymphoproliferation vs. lymphoma. Medscape

**2) Splenectomy—**generally discouraged. Historically done for refractory cytopenias, it often fails to give durable remission and raises lifelong sepsis risk. Modern guidance is to avoid it by using steroid-sparing immunosuppressants (e.g., sirolimus, MMF). PMC+2Frontiers+2

3) HSCT procedures. Not “surgery” in the classic sense but a complex inpatient transplant process at specialist centers, reserved for rare, refractory cases. Medscape

---

Prevention & everyday protection

1. Keep vaccinations current (inactivated vaccines routinely; live vaccines only if the care team approves). NCBI

2. Seek urgent care for fever with severe neutropenia or if you’re on significant immunosuppression. NCBI

3. Avoid high-impact contact sports with an enlarged spleen. NCBI

4. Prefer steroid-sparing strategies; limit repeated high-dose steroid bursts where possible. PMC

5. Keep an emergency card listing diagnosis, spleen status, medicines, and allergies. NCBI

6. Routine cancer vigilance (report B symptoms: fevers, night sweats, weight loss). PMC

7. Avoid unnecessary splenectomy; if already asplenic, follow sepsis prevention plans (vaccines, prompt antibiotics per clinician). Medscape

8. Maintain dental/skin hygiene to cut bacterial burden. NCBI

9. Coordinate pregnancy plans with your team if on immunosuppressants. NCBI

10. Attend scheduled monitoring (blood counts, DNT cells) even when you feel well. NCBI+1

---

When to see a doctor urgently

Seek immediate care for: high fever, rigors, severe sore throat with low neutrophils, sudden pallor or shortness of breath (possible severe anemia), heavy bruising/bleeding (possible thrombocytopenia), rapidly enlarging or painful spleen, or B-symptoms (fevers, drenching night sweats, weight loss) that could signal lymphoma or severe infection. NCBI+1

---

What to eat and what to avoid

Eat: balanced meals rich in fruits/vegetables, lean proteins, whole grains, and adequate calcium/vitamin D—especially during steroid use or recovery from flares. Correct iron/B12/folate only if deficient. Stay well-hydrated. NCBI

Avoid/limit: raw or undercooked meats/eggs during severe neutropenia; high-risk unpasteurized products; excess alcohol (bone marrow suppression); herbal “immune boosters” that may interact with immunosuppressants (always check with your team). No food cures ALPS; the aim is steady nutrition and safety. NCBI

---

Frequently asked questions

1) Is ALPS the same as Canale-Smith syndrome?
Yes. Canale-Smith is the older name; ALPS is the modern term based on the biology of defective lymphocyte apoptosis. Primary Immune

2) What causes ALPS?
Pathogenic variants in FAS, FASLG, or CASP10 (or somatic FAS variants in blood cells) prevent normal immune-cell death after activation. NCBI+1

3) How is ALPS diagnosed?
Typical history plus labs showing elevated double-negative T cells and evidence of defective apoptosis; genetic testing supports classification. NCBI+1

4) What are double-negative T cells and why do they matter?
They are T cells that express TCRαβ but lack CD4 and CD8; their increase is a hallmark of ALPS. PMC

5) Does ALPS get better with age?
Lymph node and spleen enlargement can lessen with age, but autoimmunity may recur and cancer risk persists, so lifelong follow-up is needed. PubMed+1

6) What’s first-line treatment for a bad blood-count flare?
Short courses of corticosteroids; then move to steroid-sparing agents (e.g., MMF, sirolimus) to prevent repeated steroid exposure. PMC

7) Why do experts try to avoid splenectomy?
Because it often fails to give durable control and increases lifelong sepsis risk. Frontiers+1

8) Is rituximab useful?
It can help some refractory cytopenias, but is generally avoided or used cautiously in ALPS due to infection/hypogammaglobulinemia risks and lack of effect on the core T-cell defect. PMC+1

9) Is sirolimus really different?
Yes. By blocking mTOR in T cells, sirolimus can shrink lymphoid tissues and control autoimmunity, often allowing steroid taper. ASH Publications

10) Is there a cure?
HSCT can cure ALPS but is reserved for severe, refractory disease due to transplant risks. Medscape

11) What is the cancer risk?
Risk for Hodgkin and non-Hodgkin lymphoma is significantly elevated compared with the general population; vigilance is important. NCBI

12) Can adults be diagnosed for the first time?
Yes—while many cases start in childhood, adults can be recognized later. Children’s Hospital of Philadelphia

13) Are live vaccines allowed?
Case-by-case; generally avoid during significant immunosuppression. Inactivated vaccines are recommended. NCBI

14) Do diets or supplements treat ALPS?
No diet or supplement corrects the apoptosis defect; focus on balanced nutrition and correcting proven deficiencies. NCBI

15) What follow-up tests matter most?
Blood counts, immunoglobulins, double-negative T cells, and clinical checks for lymphadenopathy/splenomegaly and lymphoma warning signs. NCBI+1

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 29, 2025.